GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (BSP:DVAI34) » Definitions » Valuation Rank

DaVita (BSP:DVAI34) Valuation Rank


View and export this data going back to 2019. Start your Free Trial

What is DaVita Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

DaVita Valuation Rank Related Terms

Thank you for viewing the detailed overview of DaVita's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

DaVita (BSP:DVAI34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (BSP:DVAI34) » Definitions » Valuation Rank
Comparable Companies
UHS THC CHE EHC ACHC ENSG OPCH SEM SGRY AMED HCA SAU:4013 SZSE:300015 XTER:FRE BKK:BDMS ADX:PUREHEALTH BSP:RDOR3 XTER:FME HKSE:06618 XKLS:5225
Traded in Other Exchanges
DVA:USA TRL:Germany
Address
2000 16th Street, Denver, CO, USA, 80202
Website
https://www.davita.com
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.